Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). UnicoCell Biomed Co's share price for the quarter that ended in Jun. 2026 was NT$79.5. UnicoCell Biomed Co's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 63.64 Mil. Therefore, UnicoCell Biomed Co's market cap for the quarter that ended in Jun. 2026 was NT$5,059.14 Mil.
UnicoCell Biomed Co's quarterly market cap
declined
from Dec. 2025 (NT$5,701.88 Mil) to Mar. 2026 (NT$5,027.32 Mil) but then
increased
from Mar. 2026 (NT$5,027.32 Mil) to Jun. 2026 (NT$5,059.14 Mil).
UnicoCell Biomed Co's annual market cap
declined
from Dec. 2023 (NT$4,599.58 Mil) to Dec. 2024 (NT$3,989.47 Mil) but then
increased
from Dec. 2024 (NT$3,989.47 Mil) to Dec. 2025 (NT$5,701.88 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. UnicoCell Biomed Co's Enterprise Value for Today is NT$3,918.04 Mil.
UnicoCell Biomed Co (TPE:6794) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
UnicoCell Biomed Co Market Cap Related Terms
UnicoCell Biomed Co Market Cap Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6794 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, UnicoCell Biomed Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UnicoCell Biomed Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Market Cap distribution charts can be found below:
* The bar in red indicates where UnicoCell Biomed Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
UnicoCell Biomed Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UnicoCell Biomed Co (TPE:6794) has a Market Cap of NT$4,569.14 Mil as of Aug. 22, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on UnicoCell Biomed Co and its competitors. According to the industry distribution chart, UnicoCell Biomed Co ranks #684 out of 1422 companies in the Biotechnology industry, placing it in the top 48.1%.
Is UnicoCell Biomed Co's Market Cap too high?
UnicoCell Biomed Co's current Market Cap is NT$4,569.14 Mil. Based on the distribution chart, UnicoCell Biomed Co ranks #684 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, UnicoCell Biomed Co has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UnicoCell Biomed Co ranks #684 out of 1422 companies for Market Cap. This puts UnicoCell Biomed Co in the upper half of its industry. The industry median Market Cap is 122.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 122.48, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on UnicoCell Biomed Co and its competitors. For the Biotechnology industry, the median Market Cap is 122.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UnicoCell Biomed Co's current Market Cap is NT$4,569.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$64.94, compared to a current price of NT$71.80 — trading 10.6% above its estimated fair value. The current Market Cap is NT$4,569.14 Mil. UnicoCell Biomed Co's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Market Cap is NT$4,569.14 Mil as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be overvalued.
The current stock price of NT$71.80 is trading 10.6% above its estimated GF Value™ of NT$64.94.
GuruFocus considers UnicoCell Biomed Co to be Modestly Overvalued.
Key valuation signals for TPE:6794:
Market Cap: NT$4,569.14 Mil
GF Value™: NT$64.94 vs. price of NT$71.80 (10.6% above fair value)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
80GF Score
Get the complete analysis for TPE:6794
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
